PPT-Multidrug-resistant tuberculosis :
Author : sherrill-nordquist | Published Date : 2018-11-16
update 2011 Between 2011 and 2015 Increase in TB cases tested for R amp H yearly from 08 million to 19 million 1 million multidrugresistant TB MDRTB patients
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Multidrug-resistant tuberculosis :" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Multidrug-resistant tuberculosis :: Transcript
update 2011 Between 2011 and 2015 Increase in TB cases tested for R amp H yearly from 08 million to 19 million 1 million multidrugresistant TB MDRTB patients detected and put on treatment. Prevention of spread and c ontrol of MD s in health care setting are critical and urgent as the number of antibiotic available to treat these infections is extremely limited and development of new antibiotics is not forthcoming in the foreseeable fu of Tuberculosis Internationally. Tuberculosis Control In Vulnerable Groups. Bulletin of the World Health Organization. TB is an in important public health problem in industrialized countries. Most cases occur in minority groups. P. Stogsdill, MD, FIDSA. Sept 2013. Bad bugs, No drugs. NO ESKAPE. E. nterococcus . faecium. S. taphylococcus . aureus. K. lebsiella. . pneumoniae. . C. lostridium. . difficile. A. cinetobacter. LT . Christina Jamros, DO (Associate. ) . CDR . Ryan Maves, MD (Fellow. ) . CAPT . Mary . Bavaro. , MD (Fellow). Department of Internal . Medicine. Naval . Medical Center, San Diego, CA. Disclosure. I have no relevant financial relationships with any commercial supporters.. Centers for Disease Control and Prevention. Division of Tuberculosis Elimination. 2016. . . CDC Self-Study Modules on Tuberculosis, 1-5 . Module 1: Transmission and Pathogenesis of TB. Module 2: Epidemiology of TB. Naira Dekhil. 1. , . Besma. Mhenni. 1. , Raja Haltiti. 2. , and . Helmi. Mardassi. 1. . (speaker). . 1. Unit of Typing & Genetics of . Mycobacteria. , . Institut. Pasteur de Tunis, . Tunisia. CHEMICAL RESISTANT And CATERING CHEMICAL RESISTANT LIGHT DUTY MEDIUM DUTY IMPACT RESISTANT HEAVY DUTY ABRASION RESISTANT MEDIUM DUTY HEAT RESISTANT ELECTRICAL THEMALLY INSULATED CUT RESISTANT BUTCHER GLOVE Mrs.Indumathi. Lecturer . YNC. OBJECTIVE. By the end of the session the student will be able to:. define tuberculosis. explain the epidemiological triad of tuberculosis. identify the mode of transmission and incubation period. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs Global Fire Resistant Cable Market Size, Share, Industry Trends, Growth, Outlook & Analysis 2017-2027 By Insulation Material (Cross-Linked Polyethylene (XLPE), Polyvinyl Chloride (PVC), Low Smoke Zero Halogen (LSZH), Ethylene Propylene Rubber (EPR), and Others); By End-Use Industry (Building & Construction, Manufacturing, Energy, and Others); By Region, Competitive Market Share & Forecast TB has existed since antiquity . T. he oldest unambiguously detected mycobacterium tuberculosis give evidence of the disease in the remains of bison in Wyoming dated around 17.000 years ago . TB in human can be traced back ti 9.000 years ago in Haifa archeologists found TB in remains of mother and child buried together. 1.BackgroundofresearchThereisanemergenceofmultidrugresistantbacteriawhichareunabletotreatwithmultipleantibacterialdrugs.Multidrugresistantbacterialinfectionsarebecominganimportantproblemfacinghealthca Last Updated: December 28, 2022. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Subcutaneous . Lenacapavir. Administer as Subcutaneous Injection. Take with or without food. Oral . Lenacapavir. Lenacapavir. John Stelling, MD, MPH, . jstelling@whonet.org. Brigham and Women’s Hospital, Harvard Medical School, Boston. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. Webinar agenda. Comments on the WHONET Webinar series.
Download Document
Here is the link to download the presentation.
"Multidrug-resistant tuberculosis :"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents